Iovance BiotherapeuticsNASDAQ: IOVA

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

Iovance's shares took off earlier this year after its cell therapy obtained accelerated approval. The company, however, still remains deeply unprofitable and is burning through cash at a high rate.

Iovance Biotherapeutics makes a cell therapy called Amtagvi for melanoma. Amtagvi isn't currently approved as a first-line treatment.

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events:

SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on developing innovative TIL therapies for cancer patients, announced that on May 16, 2024, the Company approved the grant of stock options covering 153,930 shares of Iovance's common stock to thirty new, non-executive employees.

Investors are expected to closely watch Iovance's (IOVA) advancement in launching a newly approved melanoma drug and anticipate an update on its early-stage pipeline.

Iovance Biotherapeutics (NASDAQ: IOVA) shares have surged recently as investors anticipate the upcoming financial results, with a nearly 6% increase on Friday and over 3% on Monday.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotech company specializing in developing unique TIL therapies for cancer patients, will release its Q1 2024 financial results on May 9, 2024. A conference call and webcast will follow at 4:30 p.m. ET for a discussion on the results and company updates.

On April 30, 2024, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotech company specializing in creating and providing new polyclonal tumor infiltrating lymphocyte (TIL) treatments for cancer patients, revealed that its senior executives will be speaking at upcoming conferences.